Fig. 5
From: Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
Adverse event (AE) profile and reasons for discontinuation. Part A AE occured in 46.0% of patients, with lymphopenia being the most common (38.1%). This was followed by elevated liver enzymes (20.0%) and arterial hypertension (16.2%). Part B The most common AE being a reason for discontinuation was vertigo (15.2%). When comparing AE in general and AE that led to discontinuation, a different distribution was observed. While hematological AE were the most common group in general AE, AE that manifested as neurological symptoms were the most common AE that led to discontinuation of therapy. AE, adverse events